AT475662T - Dihydropyrazolopyrimidinonderivate - Google Patents

Dihydropyrazolopyrimidinonderivate

Info

Publication number
AT475662T
AT475662T AT07742843T AT07742843T AT475662T AT 475662 T AT475662 T AT 475662T AT 07742843 T AT07742843 T AT 07742843T AT 07742843 T AT07742843 T AT 07742843T AT 475662 T AT475662 T AT 475662T
Authority
AT
Austria
Prior art keywords
dihydropyrazolopyrimidinonderivate
Prior art date
Application number
AT07742843T
Other languages
German (de)
Inventor
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Makoto Bamba
Keiji Takahashi
Hidetomo Furuyama
Takeshi Sagara
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2006124208 priority Critical
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Priority to PCT/JP2007/059408 priority patent/WO2007126122A1/en
Publication of AT475662T publication Critical patent/AT475662T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
AT07742843T 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinonderivate AT475662T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059408 WO2007126122A1 (en) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinone derivatives

Publications (1)

Publication Number Publication Date
AT475662T true AT475662T (en) 2010-08-15

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07742843T AT475662T (en) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinonderivate

Country Status (39)

Country Link
US (4) US7935708B2 (en)
EP (2) EP2017278B1 (en)
JP (2) JP4513919B2 (en)
KR (1) KR101409161B1 (en)
CN (1) CN101432284B (en)
AR (1) AR060635A1 (en)
AT (1) AT475662T (en)
AU (1) AU2007244185B2 (en)
BR (1) BRPI0710081A2 (en)
CA (1) CA2650119C (en)
CR (1) CR10359A (en)
CY (1) CY1118526T1 (en)
DE (1) DE602007008085D1 (en)
DK (2) DK2016080T3 (en)
DO (1) DOP2007000084A (en)
EC (1) ECSP088812A (en)
ES (2) ES2348751T3 (en)
GT (1) GT200800211A (en)
HK (1) HK1132498A1 (en)
HN (1) HN2008001532A (en)
HR (2) HRP20100563T1 (en)
HU (1) HUE032987T2 (en)
IL (1) IL194367A (en)
LT (1) LT2017278T (en)
MA (1) MA30428B1 (en)
MX (1) MX2008013063A (en)
MY (1) MY145408A (en)
NO (1) NO341617B1 (en)
NZ (1) NZ571196A (en)
PE (1) PE20080695A1 (en)
PL (2) PL2017278T3 (en)
PT (2) PT2016080E (en)
RU (1) RU2437885C2 (en)
SI (2) SI2016080T1 (en)
SV (1) SV2009003060A (en)
TW (1) TWI409262B (en)
UA (1) UA96152C2 (en)
WO (2) WO2007126122A1 (en)
ZA (1) ZA200807748B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (en) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd I derived from 1,2-dihydro-3H-pyrazolo [3,4-d] pyrimidin-3-one, pharmaceutical compositions comprising them and their use in the treatment of cancer
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
EP2213673B1 (en) * 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US8507504B2 (en) 2008-06-12 2013-08-13 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
JP2012511501A (en) * 2008-12-12 2012-05-24 Msd株式会社 Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP2012518598A (en) * 2009-02-25 2012-08-16 Msd株式会社 Pyrimidopyrimidoindazole derivatives
WO2011027800A1 (en) * 2009-09-02 2011-03-10 Banyu Pharmaceutical Co.,Ltd. Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor
DK2477628T3 (en) 2009-09-15 2014-11-24 Merck Sharp & Dohme Preparation of crystalline hemihydratformer of dihydropyrazolopyrimidinon
KR101884960B1 (en) 2010-11-16 2018-08-30 어레이 바이오파마 인크. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
JP5979136B2 (en) * 2011-04-27 2016-08-24 日本ゼオン株式会社 Polymerizable compound, polymerizable composition, polymer, and optical anisotropic body
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CA2851640A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP6290237B2 (en) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Compositions and methods for treating cancer
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
EP3235505A4 (en) * 2014-12-17 2018-01-24 Delta-Fly Pharma, Inc. Pharmaceutical composition for treatment or palliation of elderly or end-stage cancer patient
UY36629A (en) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas as modulators of TNF signaling
TW201702247A (en) 2015-04-17 2017-01-16 艾伯維有限公司 Indazolones as modulators of TNF signaling
TW201710257A (en) 2015-04-17 2017-03-16 艾伯維有限公司 Tricyclic modulators of TNF signaling
CN105130986B (en) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 Pyrimidine or pyridopyridine ketone compounds and its application
JP2018536651A (en) * 2015-11-01 2018-12-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレイト Wee1 kinase inhibitor and methods of making and using the same
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CN106719769A (en) * 2016-11-28 2017-05-31 山东农业大学 A kind of disease pest containing lentinan, Difenoconazole and thiacloprid is simultaneous to control composition pesticide
WO2018133829A1 (en) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one derivative as wee1 inhibitor
WO2018171633A1 (en) * 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
KR20190130621A (en) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Combination of CHK1 Inhibitors and WEE1 Inhibitors
TW201910335A (en) * 2017-08-01 2019-03-16 美商薩諾皇家麥爾斯通有限責任公司 -3H- 1,2-dihydro-pyrazolo [3,4-d] pyrimidin-3-one analogs
WO2019037678A1 (en) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 Pyrazolo[3,4-d]pyrimidin-3-one derivative, pharmaceutical composition and use thereof
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc Heterocyclic compounds and uses thereof
CN109810111A (en) * 2017-11-20 2019-05-28 上海医药集团股份有限公司 A kind of pyrazolone miazines compound, preparation method and application
WO2019134539A1 (en) * 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 Dihydropyrazolone and pyrimidine compound, preparation method and use therefor
WO2019165204A1 (en) * 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN108653282A (en) * 2018-06-28 2018-10-16 中国科学院昆明植物研究所 Benzothiazoles and benzopyrrole class compound application in preparation of anti-tumor drugs

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA7174A (en) 1981-08-24 1984-04-30 May & Baker Ltd New imidazotetrazionones, their preparation and the drugs that contain them.
JPH034077B2 (en) 1983-07-14 1991-01-22 Yakult Honsha Kk
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (en) * 1987-08-26 1997-07-09 三井石油化学工業株式会社 Pyrimidines and pharmaceutically acceptable salts
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
CZ51593A3 (en) 1990-09-28 1994-01-19 Smithkline Beecham Corp Water-soluble analogs of camptothecine, process of their preparation and use
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
ES2309119T3 (en) 1992-10-28 2008-12-16 Genentech, Inc. Use of antigonists of the vegf cellular growth factor.
JP3025602B2 (en) 1993-05-21 2000-03-27 デビオファーム エス.アー. Optically pure cis - oxalato (trans -l-1,2-cyclohexanediamine) platinum (II) method for producing a complex
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (en) 1996-07-04 2001-04-09 デビオファーム エス.アー. Method for producing platinum compounds
CZ27399A3 (en) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
SE0103649D0 (en) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
WO2003091255A1 (en) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05007503A (en) * 2003-01-17 2005-09-21 Warner Lambert Co 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation.
CA2515132C (en) * 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
PT1775298E (en) 2004-07-01 2013-06-12 Daiichi Sankyo Co Ltd Thienopyrazole derivative having pde7 inhibitory activity
US7947695B2 (en) * 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
AR060635A1 (en) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd I derived from 1,2-dihydro-3H-pyrazolo [3,4-d] pyrimidin-3-one, pharmaceutical compositions comprising them and their use in the treatment of cancer

Also Published As

Publication number Publication date
AU2007244185B2 (en) 2012-10-04
MA30428B1 (en) 2009-05-04
RU2008146759A (en) 2010-06-10
KR101409161B1 (en) 2014-06-19
NO20084968L (en) 2008-11-26
US20110189130A1 (en) 2011-08-04
NO341617B1 (en) 2017-12-11
CN101432284A (en) 2009-05-13
CR10359A (en) 2009-02-19
LT2017278T (en) 2017-01-25
MX2008013063A (en) 2008-12-16
WO2007126122A1 (en) 2007-11-08
NZ571196A (en) 2011-03-31
SV2009003060A (en) 2009-04-28
UA96152C2 (en) 2011-10-10
IL194367A (en) 2014-12-31
BRPI0710081A2 (en) 2011-08-02
PE20080695A1 (en) 2008-06-28
DK2017278T3 (en) 2017-02-13
ES2609087T3 (en) 2017-04-18
US7834019B2 (en) 2010-11-16
GT200800211A (en) 2009-04-07
DOP2007000084A (en) 2007-12-31
PL2017278T3 (en) 2017-10-31
SI2017278T1 (en) 2017-05-31
WO2007126128A1 (en) 2007-11-08
EP2016080A1 (en) 2009-01-21
CA2650119A1 (en) 2007-11-08
CA2650119C (en) 2017-03-14
AR060635A1 (en) 2008-07-02
CN101432284B (en) 2012-08-15
PL2016080T3 (en) 2011-03-31
CY1118526T1 (en) 2017-07-12
HRP20161763T1 (en) 2017-02-24
EP2017278B1 (en) 2016-11-02
JPWO2007126128A1 (en) 2009-09-17
US20070254892A1 (en) 2007-11-01
US7935708B2 (en) 2011-05-03
EP2017278A1 (en) 2009-01-21
PT2016080E (en) 2010-10-14
HUE032987T2 (en) 2017-11-28
HRP20100563T1 (en) 2010-11-30
JP2010132689A (en) 2010-06-17
US20100063024A1 (en) 2010-03-11
EP2016080B1 (en) 2010-07-28
JP4513919B2 (en) 2010-07-28
ECSP088812A (en) 2008-11-27
ZA200807748B (en) 2009-10-28
KR20090017491A (en) 2009-02-18
DE602007008085D1 (en) 2010-09-09
SI2016080T1 (en) 2011-03-31
RU2437885C2 (en) 2011-12-27
PT2017278T (en) 2017-01-03
US20140303178A1 (en) 2014-10-09
ES2348751T3 (en) 2010-12-13
US8791125B2 (en) 2014-07-29
AU2007244185A1 (en) 2007-11-08
MY145408A (en) 2012-02-15
DK2016080T3 (en) 2010-11-22
HK1132498A1 (en) 2013-02-15
HN2008001532A (en) 2009-06-10
TW200811176A (en) 2008-03-01
EP2017278A4 (en) 2009-04-22
TWI409262B (en) 2013-09-21
JP5167291B2 (en) 2013-03-21
IL194367D0 (en) 2009-08-03
EP2016080A4 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
DK2081937T3 (en) Triazolopyridazine-proteinkinasemodulatorer
DK2096917T3 (en) Cyclopamine-ANALOGS
DK2033551T3 (en) Kapselperforeringsmodul
DK2032057T3 (en) Elektrodeindføringsindretning
DK2091663T3 (en) Ultralydsvæskeforstøver
DK1971249T3 (en) Törreapparat
DK2038356T3 (en) Væskehærdning
DK2076760T3 (en) Fasekontrastafbildning
AT540395T (en) Anzeigeansteuersysteme
AT465907T (en) Verschlusskappe
DE602007007896D1 (en) Schienbeinkopfausgleichsosteotomieplatte
AT443753T (en) Nuancierungsmittel
DE602007013009D1 (en) Esh-networks
DE502007007057D1 (en) Wischblatt
AT475662T (en) Dihydropyrazolopyrimidinonderivate
AT457743T (en) Hydrogen-atomizers
DE602007013937D1 (en) torantagonisten
DE602007013853D1 (en) Mageninvaginationsvorrichtung
AT530853T (en) Strahlrohrbratrost
AT546501T (en) Bördelfalzverklebung
DE602007003893D1 (en) Kippambossanordnung
DE602007008851D1 (en) ektionsmittel
DK1974615T3 (en) Proteingeldannelse
AT483711T (en) Spiroindolinonderivate
DE602007002588D1 (en) Axialgebläseanordnung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2016080

Country of ref document: EP

EEIH Change in the person of patent owner